Sight Sciences to Present at Morgan Stanley Global Healthcare Conference
MENLO PARK, Calif., Sept. 01, 2026 /CourierPR/ -- On Tuesday, September 15, 2026, at 6:15 am PT / 9:15 am ET, management from Sight Sciences, Inc. (Nasdaq: SGHT) will present at the Morgan Stanley Global Healthcare Conference in New York, NY. The company, known for developing and commercializing innovative interventional technologies to improve eye care, will provide insights into its latest advancements and strategic plans.
Attendees at the conference will have the opportunity to listen to a live webcast of the presentation, which will be available on the company’s website. Interested parties can access the archived version through the “Investors” section at: [https://investors.sightsciences.com/].
Sight Sciences focuses on addressing the world’s most prevalent eye diseases through minimally invasive or non-invasive approaches. The company's OMNI® Surgical System and OMNI® Edge Surgical System are implant-free technologies designed to reduce intraocular pressure in patients with primary open-angle glaucoma. These systems are CE Marked for treating open-angle glaucoma, making them a significant advancement in the field.
The SION® Surgical System, a bladeless, manually operated device, is used to excise the trabecular meshwork in ophthalmic surgical procedures. Additionally, the company's TearCare® System, cleared by the FDA under 510(k) for treating evaporative dry eye disease, offers a thermal-activated gland expression therapy that enhances meibomian gland function in adult patients.
"Our presentation at the Morgan Stanley Global Healthcare Conference will highlight our commitment to transforming eye care through innovative solutions," said Philip Taylor, Chief Executive Officer of Sight Sciences. "We are excited to share our latest advancements and discuss the potential impact they could have on patient care."
Glaucoma, the leading cause of irreversible blindness worldwide, continues to be a major focus for Sight Sciences. Their technology aims to provide more effective treatment paradigms that enhance patient care and replace outdated approaches.